Saturday, 5 September 2026European Markets

SALMONES CAMANCHAC Stock Was Up By 16.5% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with SALMONES CAMANCHAC (SACAM.OL) rising 16.5% to kr24.00 on Tuesday while Oslo Børs Benchmark Index_GI dropped 2.2% to kr1,397.48.

SALMONES CAMANCHAC's last close was kr20.60, 51.42% below its 52-week high of kr42.40.

About SALMONES CAMANCHAC

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. (SNSE:SALMOCAM) operates as a subsidiary of Camanchaca S.A. (SNSE:CAMANCHACA).

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-0.87.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -7.32%.

Yearly Top and Bottom Value

SALMONES CAMANCHAC's stock is valued at kr24.00 at 22:31 EST, way below its 52-week high of kr42.40 and way higher than its 52-week low of kr13.60.

Volatility

SALMONES CAMANCHAC's last week, last month's, and last quarter's current intraday variation average was 0.33%, 1.15%, and 8.42%.

SALMONES CAMANCHAC's highest amplitude of average volatility was 8.17% (last week), 11.42% (last month), and 8.42% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SALMONES CAMANCHAC's stock is considered to be overbought (>=80).

Sales Growth

SALMONES CAMANCHAC's sales growth is 70.5% for the ongoing quarter and 17.2% for the next.

More news about SALMONES CAMANCHAC (SACAM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com